Clinical Trial: A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title:
Brief Summary: This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.
Detailed Summary:
Sponsor: Allergan
Current Primary Outcome:
- Dose of Botulinum Toxin Used to Treat Cervical Dystonia [ Time Frame: 2 Years ]The average dose of botulinum toxin received per patient per year was calculated.
- Dose of Botulinum Toxin Used to Treat Blepharospasm [ Time Frame: 2 Years ]The average dose of botulinum toxin received per patient per year was calculated.
Original Primary Outcome:
- Dose of Botulinum Toxin Used to Treat Cervical Dystonia [ Time Frame: 1 Year ]
- Dose of Botulinum Toxin Used to Treat Blepharospasm [ Time Frame: 1 Year ]
Current Secondary Outcome:
- Number of Participants With Adverse Events [ Time Frame: 2 Years ]An Adverse Event was any unfavorable and unintended sign, symptom, or disease documented in the medical chart that occurred after treatment with botulinum toxin, or pre-existing conditions that worsened during the retrospective period.
- Botulinum Toxin Inter-injection Interval [ Time Frame: 2 Years ]Injection-interval was the time in weeks between injections of botulinum toxin.
Original Secondary Outcome: Number of Participants With Adverse Events [ Time Frame: 1 Year ]
Information By: Allergan
Dates:
Date Received: March 18, 2013
Date Started: January 2013
Date Completion:
Last Updated: June 4, 2014
Last Verified: June 2014